Rasmussen J T, Rosendal J, Knudsen J
Institute of Biochemistry, Odense University, Denmark.
Biochem J. 1993 Jun 15;292 ( Pt 3)(Pt 3):907-13. doi: 10.1042/bj2920907.
It is shown that acyl-CoA binding protein (ACBP), in contrast with fatty acid binding protein (FABP), stimulates the synthesis of long-chain acyl-CoA esters by mitochondria. ACBP effectively opposes the product feedback inhibition of the long-chain acyl-CoA synthetase by sequestration of the synthesized acyl-CoA esters. Feedback inhibition of microsomal long-chain acyl-CoA synthesis could not be observed, due to the formation of small acyl-CoA binding vesicles during preparation and/or incubation. Microsomal membrane preparations are therefore unsuitable for studying feedback inhibition of long-chain acyl-CoA synthesis. ACBP was found to have a strong attenuating effect on the long-chain acyl-CoA inhibition of both acetyl-CoA carboxylase and mitochondrial adenine nucleotide translocase. Both processes were unaffected by the presence of long-chain acyl-CoA esters when the ratio of long-chain acyl-CoA to ACBP was below 1, independent of the acyl-CoA concentration used. It is therefore not the acyl-CoA concentration as such which is important from a regulatory point of view, but the ratio of acyl-CoA to ACBP. The cytosolic ratio of long-chain acyl-CoA to ACBP was shown to be well below 1 in the liver of fed rats. ACBP could compete with the triacylglycerol-synthesizing pathway, but not with the phospholipid-synthesizing enzymes, for acyl-CoA esters. Furthermore, in contrast with FABP, ACBP was able to protect long-chain acyl-CoA esters against hydrolysis by microsomal acyl-CoA hydrolases. The results suggest that long-chain acyl-CoA esters synthesized for either triacylglycerol synthesis or beta-oxidation have to pass through the acyl-CoA/ACBP pool before utilization. This means that acyl-CoA synthesized by microsomal or mitochondrial synthetases is uniformly available in the cell. It is suggested that ACBP has a duel function in (1) creating a cytosolic pool of acyl-CoA protected against acyl-CoA hydrolases, and (2) protecting vital cellular processes from being affected by long-chain acyl-CoA esters.
研究表明,与脂肪酸结合蛋白(FABP)不同,酰基辅酶A结合蛋白(ACBP)可刺激线粒体合成长链酰基辅酶A酯。ACBP通过隔离合成的酰基辅酶A酯,有效地对抗长链酰基辅酶A合成酶的产物反馈抑制。由于在制备和/或孵育过程中形成了小的酰基辅酶A结合囊泡,未观察到微粒体长链酰基辅酶A合成的反馈抑制。因此,微粒体膜制剂不适用于研究长链酰基辅酶A合成的反馈抑制。研究发现,ACBP对长链酰基辅酶A对乙酰辅酶A羧化酶和线粒体腺嘌呤核苷酸转位酶的抑制具有很强的减弱作用。当长链酰基辅酶A与ACBP的比例低于1时,这两个过程均不受长链酰基辅酶A酯存在的影响,与所使用的酰基辅酶A浓度无关。因此,从调节的角度来看,重要的不是酰基辅酶A的浓度本身,而是酰基辅酶A与ACBP的比例。在喂食大鼠的肝脏中,长链酰基辅酶A与ACBP的胞质比例显示远低于1。ACBP可以与三酰甘油合成途径竞争酰基辅酶A酯,但不能与磷脂合成酶竞争。此外,与FABP不同,ACBP能够保护长链酰基辅酶A酯不被微粒体酰基辅酶A水解酶水解。结果表明,为三酰甘油合成或β-氧化而合成的长链酰基辅酶A酯在利用之前必须通过酰基辅酶A/ACBP池。这意味着微粒体或线粒体合成酶合成的酰基辅酶A在细胞中是均匀可用的。有人提出,ACBP具有双重功能:(1)创建一个免受酰基辅酶A水解酶影响的胞质酰基辅酶A池;(2)保护重要的细胞过程不受长链酰基辅酶A酯的影响。